XIDORGEX Trademark

Trademark Overview

On Thursday, October 3, 2019, a trademark application was filed for XIDORGEX with the United States Patent and Trademark Office. The USPTO has given the XIDORGEX trademark a serial number of 88640402. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 8, 2023. This trademark is owned by Pfizer Inc.. The XIDORGEX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
xidorgex

General Information

Serial Number88640402
Word MarkXIDORGEX
Filing DateThursday, October 3, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 8, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 11, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 7, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, May 8, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 8, 2023ABANDONMENT - NO USE STATEMENT FILED
Wednesday, September 21, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 20, 2022SOU EXTENSION 5 GRANTED
Wednesday, September 7, 2022SOU EXTENSION 5 FILED
Tuesday, September 20, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, September 7, 2022TEAS EXTENSION RECEIVED
Wednesday, September 7, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, September 7, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, September 7, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, September 7, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, March 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 2, 2022SOU EXTENSION 4 GRANTED
Wednesday, March 2, 2022SOU EXTENSION 4 FILED
Wednesday, March 2, 2022TEAS EXTENSION RECEIVED
Thursday, September 16, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 14, 2021SOU EXTENSION 3 GRANTED
Tuesday, September 14, 2021SOU EXTENSION 3 FILED
Tuesday, September 14, 2021TEAS EXTENSION RECEIVED
Wednesday, March 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 1, 2021SOU EXTENSION 2 GRANTED
Monday, March 1, 2021SOU EXTENSION 2 FILED
Monday, March 1, 2021TEAS EXTENSION RECEIVED
Saturday, September 12, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 10, 2020SOU EXTENSION 1 GRANTED
Thursday, September 10, 2020SOU EXTENSION 1 FILED
Thursday, September 10, 2020TEAS EXTENSION RECEIVED
Tuesday, April 7, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 11, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 11, 2020PUBLISHED FOR OPPOSITION
Tuesday, February 4, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 4, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, January 30, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, January 30, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, January 22, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, January 8, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 8, 2020ASSIGNED TO EXAMINER
Monday, October 7, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 7, 2019NEW APPLICATION ENTERED

Related Keywords

xidorgex preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological